SEC 13F Intelligence

Managers / Q2 2022 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$285M
Q2 2022
Positions
50
Filings on Record
24
2019–present window
Filed
Aug 15, 2022
original filing

Summary

Endurant Capital Management LP reported $285M in U.S.-listed holdings across 50 positions for Q2 2022.

Its largest position, Invacare, represents 17.5% of the portfolio.

Compared with Q1 2022, the fund opened 19 new positions and exited 32.

Portfolio Metrics

Turnover
+31.2%
vs prior filed quarter
Top-10 Concentration
+55.7%
share of reported value
Largest Position
+17.5%
Invacare
New / Exited
19 / 32
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 52.6%US DOMESTIC: 17.5%Other: 14.4%ETP: 8.8%ADR: 3.3%Other: 3.2%
  • Common Stock · 52.6% · $150M
  • US DOMESTIC · 17.5% · $50M
  • Other · 14.4% · $41M
  • ETP · 8.8% · $25M
  • ADR · 3.3% · $9M
  • Other · 3.2% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BSXBOSTON SCIENTIFIC CORPNEW+418.2K418.2K+$16M$16M
ICON PLCNEW+49.7K49.7K+$11M$11M
ZTSZOETIS INCNEW+41.1K41.1K+$7M$7M
SGENUSDSEAGEN INCNEW+32.9K32.9K+$6M$6M
BAXBAXTER INTL INCNEW+89.9K89.9K+$6M$6M
NDQINVESCO QQQ TRNEW+13.3K13.3K+$4M$4M
TEVATEVA PHARMACEUTICAL INDS LTDNEW+459.8K459.8K+$3M$3M
NBIXNEUROCRINE BIOSCIENCES INCNEW+28.0K28.0K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

46 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1INVACARE CORPNOTE 5.000%11/120.79%$59M66.82M
2QIAGEN NVSHS NEW6.59%$19M398.2K
3BSXBOSTON SCIENTIFIC CORPhistory →COM5.47%$16M418.2K
4AVTRAVANTOR INChistory →COM4.92%$14M450.8K
5HUMHUMANA INChistory →COM4.45%$13M27.1K
6ICON PLCSHS3.78%$11M49.7K
7CICIGNA CORP NEWhistory →COM3.73%$11M40.4K
8HO1HOLOGIC INChistory →COM3.10%$9M127.7K
9LABORATORY CORP AMER HLDGSCOM NEW2.85%$8M34.7K
10ELUTAZIYO BIOLOGICS INChistory →CL A COM STK2.81%$8M1.13M
11BUWABIO RAD LABS INChistory →CL A2.78%$8M16.0K
12ZTSZOETIS INChistory →CL A2.48%$7M41.1K
13SELECTA BIOSCIENCES INCCOM2.12%$6M4.61M
14SGENUSDSEAGEN INChistory →COM2.04%$6M32.9K
15CNCCENTENE CORP DELhistory →COM2.03%$6M68.3K
16BAXBAXTER INTL INChistory →COM2.02%$6M89.9K
17SIBNSI-BONE INChistory →COM1.99%$6M430.2K
18MCKMCKESSON CORPhistory →COM1.83%$5M16.0K
19TEVATEVA PHARMACEUTICAL INDS LTDhistory →SPONSORED ADS1.21%$3M459.8K
20ADAPYADAPTIMMUNE THERAPEUTICS PLChistory →SPONDS ADR1.09%$3M1.82M
21OCULOCULAR THERAPEUTIX INChistory →COM1.07%$3M760.2K
22GALAPAGOS NVSPON ADR1.01%$3M51.4K
23IM8NINSMED INCCOM PAR $.010.98%$3M142.1K
24NBIXNEUROCRINE BIOSCIENCES INCCOM0.96%$3M28.0K
25GBTUSDGLOBAL BLOOD THERAPEUTICS INCOM0.91%$3M81.0K
26THCTENET HEALTHCARE CORPCOM NEW0.87%$2M47.4K
27INCYINCYTE CORPCOM0.83%$2M31.2K
28SPDR SER TRS&P BIOTECH0.82%$2M31.3K
29BMRNBIOMARIN PHARMACEUTICAL INCCOM0.76%$2M26.0K
30DC4DEXCOM INCCOM0.68%$2M26.0K
31SUTRO BIOPHARMA INCCOM0.65%$2M357.5K
32FATEFATE THERAPEUTICS INCCOM0.62%$2M71.6K
33RCUSARCUS BIOSCIENCES INCCOM0.58%$2M64.8K
34ABGAMERISOURCEBERGEN CORPCOM0.57%$2M11.5K
35MMSIMERIT MED SYS INCCOM0.39%$1M20.2K
36ACHCACADIA HEALTHCARE COMPANY INCOM0.38%$1M16.2K
37ZBHZIMMER BIOMET HOLDINGS INCCOM0.37%$1M9.9K
38BDQMALBIREO PHARMA INCCOM0.26%$751,00037.8K
39HORIZON THERAPEUTICS PUB LSHS0.24%$674,0008.5K
40MRVIMARAVAI LIFESCIENCES HLDGS ICOM CL A0.23%$654,00023.0K
41AXSMAXSOME THERAPEUTICS INCCOM0.20%$584,00015.2K
42ADC THERAPEUTICS SASHS0.16%$469,00059.0K
43CYTKCYTOKINETICS INCCOM NEW0.16%$453,00011.5K
44BIODESIX INCCOM0.08%$214,000130.8K
45PRAXIS PRECISION MEDICINES ICOM0.07%$194,00079.1K
46VTLUSDIMMUNIC INCCOM0.04%$106,00030.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.